AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Real-Time Price · USD

4.240

-0.230 (-5.15%)

At close: Aug 1, 2025, 4:00 PM

4.220

-0.020 (-0.47%)

After-hours: Aug 1, 2025, 7:59 PM EDT

CTI BioPharma Employees

AbCellera Biologics had 596 employees as of December 31, 2024. The number of employees increased by 10 or 1.71% compared to the previous year.

Employees

596

Change (1Y)

10

Growth (1Y)

1.71%

Revenue / Employee

$38,782

Profits / Employee

-$281,658

Market Cap

1.27B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	596	10	1.71%
Dec 31, 2023	586	91	18.38%
Dec 31, 2022	495	109	28.24%
Dec 31, 2021	386	180	87.38%
Dec 31, 2020	206	99	92.52%
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

ABCL News

25 days ago - AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
2 months ago - AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - Business Wire
2 months ago - AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - Business Wire
2 months ago - AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Business Wire
3 months ago - AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting - Business Wire
3 months ago - AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript - Seeking Alpha
3 months ago - AbCellera Reports Q1 2025 Business Results - Business Wire
3 months ago - AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 - Business Wire